• Capital Confidence Barometer: Life Sciences 2015

    EY’s 12th Capital Confidence Barometer shows the Life Sciences sector enjoying a marked increase in confidence and robust deal pipelines in the pharma and biotech industries.

  • Cash on prescription 2015

    The results from our analysis of big pharma companies show an acceleration in the pace of improvement in working capital.

  • Can social media give dealmakers an edge?

    Leading dealmakers are utilizing social media analytics to gain a competitive advantage on market trends and in enhancing their due diligence and valuation efforts.

  • Pharma Business CASETM - Commercial Analytics Suite

    CASETM is built for pharma and drives actionable insights that optimize commercial strategy and execution.

  • Biotechnology Industry Report 2015

    The biotech sector reached new heights in 2014, setting records in key financial metrics and achieving several high-profile product breakthroughs and scientific advancements.

  • How 'fit' is your capital allocation strategy?

    Biopharma management teams and boards of directors should proactively assess the “fitness” of their capital allocation strategies and exercise their inner activists to improve long-term value.

  • Financial reporting briefs - life sciences

    This edition highlights the latest developments in financial reporting for Q4 2014 including highlights from the AICPA National conference, accounting updates and regulatory developments.

  • Pharmaceutical R&D tax incentives

    Globalization of the pharmaceutical industry and increased outsourcing have drastically changed the R&D landscape. This report explores the impact on R&D tax incentives.

  • Global Corporate Divestment Study

    Are you considering divesting assets? If not, you should be. Our global study explains why and highlights the strategies to increase speed and value.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:




Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY Webcast: Revenue recognition standard for life sciences companies.

EY -  Webcast: Revenue recognition standard for life sciences companies.

Join us on 15 June for a discussion on the implications of the new revenue recognition standard for life sciences companies and how companies should plan for implementation.

Megatrends - Health reimagined

EY - Megatrends - Health reimagined

Health care is embarking on a once-in-a-lifetime transformation. This report explores what the industry needs to do to achieve future success.